ATLANTA—The RTS,S/AS01 candidate malaria vaccine — being tested in seven African countries — is safe, and gave protection to a third of all babies vaccinated between the ages of six and 12 weeks during the first year of follow up. These findings were announced at the American Society of Tropical Medicine and Hygiene annual meeting in Atlanta, Georgia, by Dr Patricia Njuguna from the Kenya Medical Research Institute in Kilifi, Kenya and Dr John Lusingu of the National Institute for Medical Research in Tanga, Tanzania. The researchers explain that — together with previous findings in children vaccinated between five and 17 months of age —these interim results demonstrate that RTS,S/AS01 could become an important component of malaria control combined with other measures including effective treatment and the use of insecticide-treated bed nets.
You may also like...
New “Point Of Care” TB Tests Urgently Needed! 17 Aug, 2009 Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer 27 Apr, 2015 Improved Health Systems Bring Greatest Benefit For The Poor 29 May, 2010 ‘Good health at low cost’ 25 years on — What makes a successful health system? The Bangladesh Miracle 24 Oct, 2011
- Previous story Malaria vaccine prevents one third of malaria cases at 12 months
- Next story MDFM News: ALZHEIMER’S DISEASE: Newly discovered mutation drastically increases risk and points to future treatments
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014